Preclinical Evaluation of a proprietary antibody for cancer treatment
Therapeutic monoclonal antibodies (mAbs) for targeted treatment of cancer are a preferred class of drugs with a huge and ever-growing market potential. Conventional mAb generating procedures have technology-based limitations in identifying novel targets and developing new mAbs targeting multimeric membrane proteins. Thus, the number of known druggable targets on cancer cells is still low, with a need to develop more effective methods to successfully and cost-effectively generate antibodies against these difficult targets in a timely manner.